MedTrace Logo

Benign Reproductive Tissue Analysis for Endometrial Cancer Markers

NCT00481754 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 359

Last updated 2020-11-17

No results posted yet for this study

Summary

Background:

* Endometrial cancer (cancer of the lining of the uterus) is the most common gynecologic cancer in the United States.
* Currently, there are no markers (components of blood and tissue that determine who might be at risk for developing cancer) for endometrial cancer.

Objectives:

-To see if women who are undergoing hysterectomy are willing to provide blood and tissue samples to help doctors identify markers that would indicate increased risk for developing endometrial cancer.

Eligibility:

-Women between 35 and 54 years of age who will undergo hysterectomy for a non-cancerous condition, such as uterine fibroids, uterine prolapse, abnormal uterine bleeding, and others at Magee-Women's Hospital in Pittsburgh, Penn.

Design:

* Patients' medical records are reviewed and patients complete a questionnaire including information on race and ethnic background, education, marital status, family history, height, weight, pregnancy history, smoking history, medication history, history about menstrual periods and menopausal symptoms.
* Patients provide blood and urine samples before surgery.
* A sample of fat tissue is removed during surgery in patients undergoing abdominal surgery.
* Tissue samples from the removed uterus (and ovaries if the ovaries are also removed) are collected and analyzed for markers for endometrial cancer.

Conditions

  • Oophorectomy for Benign Reasons
  • Hysterectomy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Nicolas Wentzensen, M.D. · National Cancer Institute (NCI)

Eligibility

Min Age
18 Years
Max Age
54 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-24
Primary Completion
2020-11-13
Completion
2020-11-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00481754 on ClinicalTrials.gov